H.C. Wainwright analyst Patrick Trucchio lowered the firm’s price target on Cybin (CYBN) to $150 from $190 and keeps a Buy rating on the shares. The firm says the company’s psychedelics pipeline is progressing on multiple fronts.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYBN:
- Cybin price target lowered to $73 from $86 at Canaccord
- Cybin Accelerates PARADIGM Program for Depression Treatment
- Psychedelic: Relmada acquires neurosteroid from Asarina
- Psychedelic: atai Life Sciences reports BPL-003 study results
- Cybin’s depression program advancing in Phase 3, says H.C. Wainwright